Core Points - The divorce dispute between Zhao Bingxian, known as "China's Buffett," and his ex-wife Lu Juan has concluded after 15 years, with a final ruling on the division of 1 billion yuan in assets [1][2] - The court ruled that Zhao Bingxian and Lu Juan will each hold 50% of the shares in Zhongzheng Wanrong Investment Group, the controlling shareholder of Wohua Pharmaceutical [2][4] - Following the ruling, Zhao Bingxian's control over Zhongzheng Wanrong has ended, resulting in the company having no actual controller [4][5] Company Overview - Wohua Pharmaceutical specializes in cardiovascular traditional Chinese medicine, with unique patented products and a significant number of items listed in national insurance and essential drug directories [6] - For the first three quarters of 2025, Wohua Pharmaceutical reported revenue of 625 million yuan, an increase of 8.31% year-on-year, and a net profit of 63.995 million yuan, up 179.34% year-on-year [6] - As of November 6, 2023, Wohua Pharmaceutical's total market capitalization reached 3.556 billion yuan [4] Historical Context - Zhao Bingxian and Lu Juan founded Zhongzheng Wanrong in 1991, initially focusing on investment banking and later expanding into various successful listings [9][14] - The couple's relationship and business partnership began in the military, where they became among China's first stock investors [9]

Core Points - The divorce dispute between Zhao Bingxian, known as "China's Buffett," and his ex-wife Lu Juan has concluded after 15 years, with a court ruling on the division of 1 billion yuan in assets [1][2] - The court's decision mandates an equal split of the shares in Zhongzheng Wanrong Investment Group, which Zhao and Lu held, resulting in each owning 50% of the company [1][3] - Following the ruling, Zhao Bingxian's status as the actual controller of the company has changed, as he previously held 80% of the shares [3][4] Company Overview - Wohua Pharmaceutical, the company involved, specializes in cardiovascular traditional Chinese medicine and has a total market value of 3.556 billion yuan as of November 6 [4] - The company reported a revenue of 625 million yuan for the first three quarters of 2025, reflecting an 8.31% year-on-year increase, and a net profit of 63.995 million yuan, up 179.34% [4] - Wohua Pharmaceutical has 162 drug approval numbers, with 15 exclusive products, and 43 products listed in the National Essential Drug List [4] Historical Context - Zhao Bingxian and Lu Juan founded Zhongzheng Wanrong Group in 1991, initially focusing on investment banking and later expanding into various successful listings [5][6][7][8][9][10][11] - The couple's personal and professional relationship has been tumultuous, marked by allegations of domestic violence and disputes over company assets since Lu filed for divorce in 2010 [1][11]

Core Viewpoint - The long-standing divorce dispute between Zhao Bingxian, known as "China's Buffett," and his ex-wife Lu Juan has concluded with a court ruling on the division of their assets, specifically regarding their stake in Zhongzheng Wanrong Investment Group, valued at 10 billion yuan [1][2]. Group 1: Court Ruling and Financial Implications - The Beijing Third Intermediate People's Court ruled that Zhao Bingxian and Lu Juan will equally split their shares in Zhongzheng Wanrong, resulting in each holding 50% of the equity [2][4]. - The court's decision does not affect Zhongzheng Wanrong's 50.27% stake in Wohuayi Pharmaceutical, which remains the controlling shareholder of the company [3][4]. - Following the ruling, Zhao Bingxian's "divorce settlement" amounts to 536 million yuan, based on the company's market capitalization of 3.556 billion yuan as of November 6 [4][5]. Group 2: Company Background and Performance - Wohuayi Pharmaceutical specializes in cardiovascular traditional Chinese medicine, with several patented products and a significant number of items listed in national medical insurance directories [5]. - For the first three quarters of 2025, Wohuayi Pharmaceutical reported revenues of 625 million yuan, an increase of 8.31% year-on-year, and a net profit of 63.995 million yuan, up 179.34% [5]. - The company continues to operate normally, with Zhao Bingxian retaining his roles as chairman and legal representative of both Zhongzheng Wanrong and Wohuayi Pharmaceutical [5].